Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Adamo · SciRah

Researcher profile · Semantic Scholar

B. Adamo

Share profile

B. Adamo — researcher profile on SciRah

h-index: 38
Works: 154
Citations: 6,935

Most-cited papers

Clinical implications of the intrinsic molecular subtypes of breast cancer.
A. Prat, E. Pineda, B. Adamo, P. Galván +6 more
2015Breast1,080 citations Open access
Semantic Scholar
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
F. Schettini, N. Chic, F. Brasó-Maristany, L. Paré +23 more
2021npj Breast Cancer564 citations Open access
Semantic Scholar
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
O. Martínez-Sáez, N. Chic, T. Pascual, B. Adamo +13 more
2020Breast Cancer Research357 citations Open access
Semantic Scholar
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
J. Tabernero, R. Bahleda, R. Dienstmann, J. Infante +15 more
2015Journal of Clinical Oncology321 citations
Semantic Scholar
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
J. Cejalvo, E. D. de Dueñas, P. Galván, S. Garcia-Recio +23 more
2017Cancer Research205 citations Open access
Semantic Scholar
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
A. Prat, Cheng Fan, A. Fernández, K. Hoadley +10 more
2015BMC Medicine161 citations Open access
Semantic Scholar
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
F. Schettini, T. Pascual, B. Conte, N. Chic +24 more
2020Cancer Treatment Reviews156 citations Open access
Semantic Scholar
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.
A. Prat, T. Pascual, C. de Angelis, C. Gutierrez +31 more
2019Journal of the National Cancer Institute144 citations Open access
Semantic Scholar
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
A. Prat, M. Cheang, P. Galván, P. Nuciforo +8 more
2016JAMA Oncology107 citations Open access
Semantic Scholar
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
E. Ciruelos, P. Villagrasa, T. Pascual, M. Oliveira +24 more
2020Clinical Cancer Research98 citations Open access
Semantic Scholar
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
F. Brasó-Maristany, G. Griguolo, T. Pascual, L. Paré +24 more
2020Nature Communications95 citations Open access
Semantic Scholar
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
A. Prat, P. Galván, B. Jímenez, Wesley Buckingham +13 more
2015Clinical Cancer Research91 citations Open access
Semantic Scholar
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L. Paré, T. Pascual, E. Seguí, C. Teixidó +29 more
2018Annals of Oncology90 citations Open access
Semantic Scholar
Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
G. Ricciardi, B. Adamo, A. Ieni, Luana Licata +5 more
2015PLoS ONE72 citations Open access
Semantic Scholar
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
A. Bardia, K. Jhaveri, K. Kalinsky, S. Pernas +20 more
2023Future Oncology64 citations Open access
Semantic Scholar
Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast cancer
O. Karginova, Marni B. Siegel, A. V. Van Swearingen, A. M. Deal +14 more
2015Molecular Cancer Therapeutics64 citations Open access
Semantic Scholar
Development of a multi-parameter prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
A. Prat, V. Guarneri, L. Paré, G. Griguolo +35 more
2020The Lancet Oncology61 citations Open access
Semantic Scholar
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
A. Prat, F. Brasó-Maristany, O. Martínez-Sáez, E. Sanfeliu +28 more
2023Nature Communications50 citations Open access
Semantic Scholar
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
G. Griguolo, F. Brasó-Maristany, B. González-Farré, T. Pascual +25 more
2020Cancers46 citations Open access
Semantic Scholar
A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse
A. Prat, A. Lluch, Arran Turnbull, A. Dunbier +21 more
2016Clinical Cancer Research46 citations Open access
Semantic Scholar
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
A. Prat, J. C. Brase, Yuan Cheng, P. Nuciforo +9 more
2019The Oncologist43 citations Open access
Semantic Scholar
Gene expression profiles of breast cancer metastasis according to organ site
F. Brasó-Maristany, L. Paré, N. Chic, O. Martínez-Sáez +18 more
2021Molecular Oncology41 citations Open access
Semantic Scholar
Intrinsic molecular subtypes of HER2+ breast cancer
A. Prat, T. Pascual, B. Adamo
2017OncoTarget41 citations Open access
Semantic Scholar
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
B. Adamo, G. Ricciardi, A. Ieni, T. Franchina +6 more
2017OncoTarget40 citations Open access
Semantic Scholar
Prognostic markers in triple-negative breast cancer (TNBC): The role of androgen receptor, e-cadherin, and Ki67.
G. Ricciardi, B. Adamo, V. Barresi, A. Ieni +6 more
201540 citations
Semantic Scholar
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
O. Martínez-Sáez, T. Pascual, F. Brasó-Maristany, N. Chic +19 more
2021npj Breast Cancer34 citations Open access
Semantic Scholar
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
B. Adamo, M. Bellet, L. Paré, T. Pascual +15 more
2019Breast Cancer Research33 citations Open access
Semantic Scholar
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies
B. Conte, F. Brasó-Maristany, Adela Rodriguez Hernández, T. Pascual +22 more
2024EBioMedicine26 citations Open access
Semantic Scholar
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
F. Brasó-Maristany, G. Griguolo, N. Chic, T. Pascual +23 more
2022Journal of the National Cancer Institute25 citations Open access
Semantic Scholar
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
A. Fernández-Martínez, T. Pascual, G. Perrone, S. Morales +29 more
2017OncoTarget25 citations Open access
Semantic Scholar
Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
T. Pascual, B. González-Farré, C. Teixidó, L. Oleaga +11 more
2019JCO Precision Oncology21 citations Open access
Semantic Scholar
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
F. Schettini, O. Martínez-Sáez, C. Falato, I. De Santo +15 more
2023ESMO Open18 citations Open access
Semantic Scholar
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
T. Pascual, Miguel Martín, A. Fernández-Martínez, L. Paré +20 more
2019Frontiers in Oncology17 citations Open access
Semantic Scholar
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
N. Chic, F. Schettini, F. Brasó-Maristany, E. Sanfeliu +19 more
2021EBioMedicine16 citations Open access
Semantic Scholar
Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
T. Pascual, A. Fernández-Martínez, M. Tanioka, M. Dieci +19 more
2021Clinical Cancer Research15 citations Open access
Semantic Scholar
Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
E. Ciruelos, P. Villagrasa, L. Paré, M. Oliveira +18 more
2019Poster Discussion Abstracts12 citations
Semantic Scholar
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
F. Schettini, N. Chic, F. Brasó-Maristany, L. Paré +23 more
20239 citations Open access
Semantic Scholar
Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
G. Ricciardi, B. Adamo, A. Ieni, Luana Licata +5 more
2015PLoS ONE9 citations Open access
Semantic Scholar
A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
J. de la Haba, A. Guerrero-Zotano, J. Pérez-Fidalgo, S. G. Santiago +16 more
20187 citations
Semantic Scholar
Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial
E. Ciruelos, P. Villagrasa, L. Paré, Marize Varella de Oliveira +18 more
20185 citations
Semantic Scholar
263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)
A. R. Hernández, O. Saez, F. Brasó-Maristany, B. Pastor +13 more
2022Annals of Oncology4 citations Open access
Semantic Scholar
15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis
B. González-Farré, P. Nuciforo, L. P. Brunet, J. Cortes +12 more
20204 citations Open access
Semantic Scholar
Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
B. Adamo, G. Ricciardi, A. Ieni, T. Franchina +6 more
2019OncoTarget4 citations Open access
Semantic Scholar
ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC).
G. Griguolo, F. Brasó-Maristany, T. Pascual, N. Chic +6 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.
T. Pascual, L. Paré, P. Galván, M. Izquierdo +9 more
20184 citations
Semantic Scholar
PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
A. Prat, J. C. Brase, Y. Cheng, P. Nuciforo +9 more
20184 citations
Semantic Scholar
55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)
F. Schettini, T. Pascual, L. Ghiglione, F. Brasó-Maristany +14 more
2023ESMO Open3 citations Open access
Semantic Scholar
132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy
T. Pascual, N. Chic, O. Saez, E. S. Torres +15 more
2022Annals of Oncology3 citations Open access
Semantic Scholar
237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
F. Brasó-Maristany, G. Griguolo, N. Chic, L. P. Brunet +16 more
2022Annals of Oncology3 citations Open access
Semantic Scholar
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
A. Prat, Yi-Hsuan Tsai, T. Pascual, L. Paré +9 more
2020Clinical Cancer Research3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Prat×33
Invite
A. Prat — researcher profile on SciRah
P. Galván×29
Invite
P. Galván — researcher profile on SciRah
L. Paré×27
Invite
L. Paré — researcher profile on SciRah
T. Pascual×25
Invite
T. Pascual — researcher profile on SciRah

×22

Invite

N. Chic — researcher profile on SciRah

Invite

M. Muñoz — researcher profile on SciRah

Invite

M. Vidal — researcher profile on SciRah

F. Brasó-Maristany×20

Invite

F. Brasó-Maristany — researcher profile on SciRah

P. Villagrasa×17

Invite

P. Villagrasa — researcher profile on SciRah

B. González-Farré×16

Invite

B. González-Farré — researcher profile on SciRah

F. Schettini×12

Invite

F. Schettini — researcher profile on SciRah

O. Martínez-Sáez×12

Invite

O. Martínez-Sáez — researcher profile on SciRah